Active Comparator EBI-005

Phase 3Small molecule

Active Comparator EBI-005 is one of 61 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic ConjunctivitisActive, not recruiting

Eye DiseaseActive, not recruiting

Allergic ConjunctivitisPhase 2

Active, not recruiting

Eye DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

2 2

Alphagan

AbbVie

Phase 3

2 3

Chantix

Pfizer

Phase 3

2 4

Bayer Aspirin

Bayer

Phase 3

1 5

Zovirax

BBp Consulting, Inc

Phase 3

2 6

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 7

CF101

CCan-Fite BioPharma

Phase 3

1 8

Carboxymethylcellulose

AbbVie

Phase 3

4 9

Refresh Plus

AbbVie

Phase 3

1 10

Csa

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Conjunctivitis1 trial

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Completed·EEleven Biotherapeutics·Phase 2·NCT02082899·150 enrolled

Eye Disease1 trial

Phase 3 Study of EBI-005 in Dry Eye Disease

Completed·EEleven Biotherapeutics·Phase 3·NCT01998802·670 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Active Comparator EBI-005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Active Comparator EBI-005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Active Comparator EBI-005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eleven Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEleven Biotherapeutics

Active Comparator EBI-005

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Conjunctivitis1 trial

Eye Disease1 trial

References

Drug Info

Quick Facts

Related News